Wound Care News
-
Infection Control Resources to Identify Klebsiella and Other Pathogens in Healthcare Settings throughout Puerto Rico
The Centers for Disease Control and Prevention (CDC) describes Klebsiella as a type of gram-negative bacteria that can cause different types of healthcare-associated infections (HAIs). These include pneumonia, bloodstream infections, wound or surgical site infections, and meningitis. The agency warns Klebsiella bacteria have increasingly developed antimicrobial resistance, most recently to the ...
-
Infection Control Resources to Mitigate Patient Exposure Risks to Klebsiella and Other Pathogens
An article published last year in Emerging Infectious Diseases detailed a notable increase of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in New York City during 2021 through June of 2022. The data for the study came from a large public healthcare system in New York City that serves more than 1.2 million people each year. The Centers for Disease Control and Prevention (CDC) ...
-
Klebsiella in Healthcare Settings Discussed in New Online Video
The IAQ Video Network and Cochrane & Associates announced the release of their latest educational video today. Their newest production discusses Klebsiella, a type of gram-negative bacteria that can cause various healthcare-associated infections (HAIs). “HAIs due to Klebsiella can include pneumonia, bloodstream infections, wound or surgical site infections, and meningitis,” said ...
-
New Partnership Established: Alfa Chemistry Adds 200,000+ Chemicals to Spaya Database
In a recent statement, the US-based chemical supplier Alfa Chemistry announced that it has added more than 200,000 chemicals to Spaya's chemical structure collection database. The partnership between Alfa Chemistry and Spaya, a platform that uses a data-driven AI approach to discover retrosynthetic routes, will provide customers with unparalleled access to a wide range of Alfa Chemistry's ...
-
Healiva Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew
Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world’s broadest portfolios of affordable, ...
By healiva SA
-
Evaluation of CO2 fractional laser beauty machine treatment effect
The most commonly used fractional laser is CO2 fractional laser beauty machine. After more than ten years of clinical application, it can be said that CO2 fractional laser skin resurfacing treatment technology is relatively safe. As long as its therapeutic energy and action density are mastered, there are generally no obvious side effects of. Bvlaser is a professional CO2 fractional laser ...
-
Creative Proteomics Cytokine Launches Growth Factors (GF) Detection Service for Your Research
Cytokine, a subdivision of Creative Proteomics, specializes in providing cytokine research and analytical services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Recently, the product manager of the company is pleased to announce the launch of the growth factors (GF) detection service for further research enhancement. ...
-
Candida auris and Infection Control Resources for Healthcare Providers
Candida auris is an emerging multidrug-resistant microorganism that was first identified in 2009 in Asia. It has quickly become a cause of severe infections around the world, including in the United States according to the Centers for Disease Control and Prevention (CDC). It is as yeast, which is a type of fungi. CDC describes Candida auris as a concerning drug-resistant fungus because it is: ...
-
XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce the commencement of an Investigational New Drug (IND) enabling safety study with its novel XF-73 Dermal formulation. This study is the second of two planned preclinical safety studies of the XF-73 ...
-
Stanford Surgeon Venita Chandra Joins Alucent Biomedical Scientific Advisory Board as Company Enters Arteriovenous Fistula Market
Alucent Biomedical, a privately held medical technology company founded to transform the way vascular disease is treated, today announced Venita Chandra, M.D., will join the company’s scientific advisory board. Dr. Chandra is board certified in both general and vascular surgery. She is a clinical associate professor of surgery in the Division of Vascular Surgery at Stanford University ...
-
Microbion Corporation Announces Data Highlighting Pravibismane’s Effect on Bacterial Energetics Presented at ASM Microbe 2022
Microbion Corporation today announced that the company presented a poster highlighting the effect of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species at ASM Microbe 2022 in Washington, DC. The objectives of these studies were to further understand the mechanism of action of pravibismane, in both planktonic and ...
-
Alfa Chemistry Announces the Launch of Extracted Peptides
Demonstrating competence in peptide R&D, production, and sales integration, the US-based chemical supplier Alfa Chemistry recently announced the launch of its peptide product line for researchers across the globe. After this move, a wide range of high-quality extracted peptides, including hydrolyzed protein peptides, fish collagen peptides, marine fish oligopeptides, oyster peptides, sea ...
-
Microbion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of Pravibismane
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued to Microbion, United States Patent No. 11,324,715 on May 10, 2022, with claims to a pharmaceutical composition of pravibismane. The patent, titled “Bismuth-thiol compositions and methods for treating wounds,” adds to Microbion’s growing portfolio of intellectual property on the ...
-
Classification of Fractional Lasers
Fractional laser is a commonly used instrument in clinical beauty medicine. In addition to treating acne scars, burn scars, and trauma scars, it also has a good effect on facial rejuvenation, freckle removal, skin shrinking, and stretch marks. Bvlaser is a CO2 fractional laser machine factory supplier, we have best fractional laser machine for sale. What is fractional laser Fractional laser ...
-
Aatru Medical Announces FDA Clearance and Commercial Launch of the NPSIMS - Negative Pressure Surgical Incision Management System
Aatru Medical, LLC ("Aatru") today announced U.S. Food and Drug Administration (FDA) 510(k) Class II clearance of the NPSIMS™ Negative Pressure Surgical Incision Management System. The NPSIMS utilizes an innovative mode-of-action that eliminates the expensive electromechanical pump, battery, and electronics found in most other negative pressure wound therapy (NPWT) systems being deployed ...
-
Candida auris and Infection Control Resources for Healthcare Facilities in Puerto Rico
Several years ago, the Centers for Disease Control and Prevention (CDC) announced it was establishing the Antibiotic Resistance Laboratory Network (AR Lab Network) in Puerto Rico and all 50 states. It was designed to help detect new forms of drug resistance as novel fungal threats emerge. Specifically mentioned in the announcement was Candida auris. CDC reported that this fungus poses a unique ...
-
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety data First adolescent patient with EB enrolled into clinical trial and completed treatment International patent granted for the use of cannabinol for the treatment of epidermolysis bullosa VANCOUVER, British Columbia, July 25, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ...
-
Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBRC, Inc. to Advance Topical Pravibismane
Microbion Corporation of Bozeman, MT, today announced that it has received non-dilutive funding through its strategic partnership with CUBRC, Inc., a Buffalo-based, independent not-for-profit research company, of up to $2.1 million from the US Navy through the Medical Technology Enterprise Consortium (MTEC) partnership. The funding project is titled “Pravibismane Suspension as a Topical, ...
-
SANUWAVE Health and JV Partner Diversa S.A. Announce Distribution Agreement with Grupo Suprimed
SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation wound care products and its JV partner Diversa S.A. have announced a new distribution agreement with Grupo Suprimed to market and sell the dermaPACE® System in the private healthcare market in Brazil. The dermaPACE® System is currently licensed or approved for advanced wound care indications in Brazil, Mexico and ...
-
SANUWAVE Health Announces Issuance of Eleven New Patents Bringing the Company`s Total Number of Active Patents and Patent Applications to 150
SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications for shockwave systems in the non-medical field, announced today the patent activity for the full year 2020 and the first quarter of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you